Updates are available Correction dated 2024-04-02
Click to view Correction: https://doi.org/10.1038/s41591-024-02947-2
-
Authors
Allen, Breanna M. http://orcid.org/0000-0002-4830-6792
Hiam, Kamir J. http://orcid.org/0000-0002-1956-0257
Burnett, Cassandra E.
Venida, Anthony
DeBarge, Rachel
Tenvooren, Iliana
Marquez, Diana M. http://orcid.org/0000-0001-5343-8696
Cho, Nam Woo
Carmi, Yaron http://orcid.org/0000-0002-0972-0616
Spitzer, Matthew H. http://orcid.org/0000-0002-5291-3819
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5OD023056, S10OD018040)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA097257)
UCSF Program for Breakthrough Biomedical Research, Parker Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 30 September 2019
Accepted: 17 April 2020
First Online: 25 May 2020
Change Date: 2 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02947-2
Competing interests
: M.H.S. receives research funding from Roche/Genentech, Bristol-Myers Squibb and Valitor and has been a paid consultant for Five Prime Therapeutics, Ono Pharmaceutical and January Inc.
